Company Profile

QSAM Biosciences, Inc. is developing nuclear medicines for the treatment of cancer and related diseases. The Companyâ€™s technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group, LLC. Iso Therapeutics Group LLC also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 with a chelating agent, DOTMP (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylenephosphonic acid). Its combination delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to take images of the skeleton and locate and characterize the size and nature of tumors.

Employees

Sector

Biotechnology & Medical Research

More about the company

03/05/24	Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.	CI
20/03/24	QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

03/05/24	Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.	CI
20/03/24	QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
20/03/24	QSAM Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	CI
14/11/23	Telix Pharmaceuticals Limited signed a non-binding term sheet to acquire QSAM Biosciences, Inc. for $33.1 million.	CI
13/11/23	QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
29/09/23	QSAM Biosciences, Inc. announced that it has received $0.600001 million in funding	CI
14/08/23	QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
14/06/23	QSAM Biosciences, Inc. Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®	CI
23/05/23	QSAM Biosciences Expands Its Study of Cyclosam(R) in the Treatment of Bone Cancer; Opens Patient Enrollment At Key Chicago Center, Insight Hospital and Medical Center	CI
15/05/23	QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
26/04/23	QSAM Biosciences, Inc. Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam	CI
05/04/23	QSAM Biosciences Inc. Opens Enrollment of Second Cohort of Patients in its Phase 1 Study of CycloSam®? Targeting Metastatic Bone Cancer	CI
31/03/23	QSAM Biosciences, Inc. announced that it has received $3 million in funding	CI

16/04/24	QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER	AQ
08/02/24	QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals	AQ
14/11/23	QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee	AQ
16/08/23	QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data	AQ
23/06/23	QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities (form 8-K)	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+1.68%	+3.55%	+4.86%	+10.97%	49.42B
REVOLUTION MEDICINES, INC.	+0.72%	+1.93%	+424.51%	+624.25%	40.34B
IQVIA HOLDINGS INC.	+2.54%	+2.84%	+27.06%	-3.62%	34.01B
BEONE MEDICINES AG	+0.31%	+4.16%	+23.87%	+59.76%	33.56B
CELLTRION, INC.	-2.09%	-0.80%	+3.56%	+33.56%	26.84B
ASCENDIS PHARMA A/S	-0.63%	+2.85%	-	-	17.22B
MEDPACE HOLDINGS, INC.	+0.66%	-1.48%	+66.05%	+127.36%	15.19B
IONIS PHARMACEUTICALS, INC.	-23.90%	-18.84%	+55.47%	+53.83%	13.96B
EUROFINS SCIENTIFIC SE	+2.59%	+0.50%	+15.28%	+21.25%	13.36B
Average	+0.66%	+0.83%	+77.58%	+115.92%	27.1B
Weighted average by Cap.	+0.77%	+0.90%	+93.37%	+138.87%

Anpath Group, Inc. Stock OTC Bulletin Board

Stocks

US03634J1060

Biotechnology & Medical Research

Latest news : Anpath Group, Inc.

Press Releases: Anpath Group, Inc.

Other Biotechnology & Medical Research

Company Profile

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-